Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3295668 in Metastatic Breast Cancer
NCT03955939Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of LY3295668 in breast cancer (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Reductions, Number of Participants with Dose Limiting Toxicities and 2 more. Started Aug 2019; status: completed.
02
Drugs
LY3295668
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03955939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955939.